Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study
Xue Ge(Nektar Therapeutics (United States)), Michael A. Eldon(Nektar Therapeutics (United States)), Carlo J. Di Fonzo(Nektar Therapeutics (United States)), Suresh Siddhanti(Amgen (United States)), Jack E. Henningfield(Univates), Janet Jobes(Nektar Therapeutics (United States)), Ute Hoch(University of Arizona), Margaret Ziola(Nektar Therapeutics (United States)), Sunny Xie(Nektar Therapeutics (United States)), Mary Tagliaferri(Nektar Therapeutics (United States)), Bradley Vince(Altasciences Clinical Research Vince & Associates), Stephen K. Doberstein(Xencor (United States)), Debra Kelsh(Altasciences Clinical Research Vince & Associates), Lin Lü(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 9
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Biochemical verification of tobacco use and cessation
|Nicotine & Tobacco Research|2002|1.8k
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana*
|Journal of Analytical Toxicology|1992|520